This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liteplo, R. G. Articles by Kerbel, R. S. Search for Related Content PubMed PubMed Citation Articles by Liteplo, R. G. Articles by Kerbel, R. S.

Reduced Levels of DNA 5-Methylcytosine in Metastatic Variants of the Human Melanoma Cell Line MeWo¹

Department of Experimental Oncology, Ottawa Regional Cancer Center, Ottawa, Ontario K1H 8L6, Canada [R. G. L.], and Division of Cancer and Cell Biology, Mount Sinai Hospital Research Institute, and the Department of Medical Genetics, University of Toronto, Toronto, Ontario M5G 1X5, Canada [R. S. K.]

The total levels of DNA 5-methylcytosine were determined in a series of related highly metastatic cell lines which had been isolated from the poorly metastatic human melanoma tumor line MeWo. The procedure used to quantitate DNA 5-methylcytosine involved labeling of DNA with [6-³H]uridine, hydrolysis with formic acid, and separation of cytosine and 5-methylcytosine bases by high-performance liquid chromatography. The DNA 5-methylcytosine content of the parental MeWo tumor was 3.07 ± 0.16%. Metastatic variants of MeWo which had been isolated using a combination of in vitro and in vivo selection procedures had DNA 5-methylcytosine levels between 2.45 ± 0.15% and 2.75 ± 0.09%. Metastatic variants which were isolated using a single step in vivo selection procedure exhibited DNA 5-methylcytosine levels of 1.92 ± 0.02% to 2.68 ± 0.09%. No consistent decreases in DNA 5-methylcytosine content were found in "artificial" metastases arising in athymic "nude" mice following the i.v. inoculation of MeWo or its cloned sublines. These observations provide further support for the hypothesis that alterations in the cytosine methylation of DNA may play an important role in the generation of tumor cell heterogeneity and the progression of tumors from relatively benign to highly malignant states.

¹ Supported by grants from the National Cancer Institute of Canada to R. G. L. and R. S. K.

² To whom requests for reprints should be addressed, at Department of Experimental Oncology, Ottawa Regional Cancer Center, General Division, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada.

³ Research Associate of the National Cancer Institute of Canada.

Received 11/ 7/86. Revised 2/ 3/87. Accepted 2/ 5/87.

This article has been cited by other articles:

				G. A. Ohnmacht, E. Wang, S. Mocellin, A. Abati, A. Filie, P. Fetsch, A. I. Riker, U. S. Kammula, S. A. Rosenberg, and F. M. Marincola Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination J. Immunol., August 1, 2001; 167(3): 1809 - 1820. [Abstract] [Full Text] [PDF]

				M. C. Panelli, M. P. Bettinotti, K. Lally, G. A. Ohnmacht, Y. Li, P. Robbins, A. Riker, S. A. Rosenberg, and F. M. Marincola A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 J. Immunol., April 15, 2000; 164(8): 4382 - 4392. [Abstract] [Full Text] [PDF]

				A Ebralidze, E Tulchinsky, M Grigorian, A Afanasyeva, V Senin, E Revazova, and E Lukanidin Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes & Dev., July 1, 1989; 3(7): 1086 - 1093. [Abstract] [PDF]